ResultsIQ

ResultsIQ › Latest results › Sudeep Pharma Limited

Sudeep Pharma Limited Q2 FY27 results deck summary

NSE: SUDEEPPHRM · BSE: 544619

Results deck of 28 Oct 2026, summarised by AI from the filing.

Sudeep Pharma's Q2 FY27 revenue rose 21% YoY to ₹196.7 cr and EBITDA 32% to ₹73.2 cr, with Nandesari supplies expected in H2 FY27.

Key takeaways

  1. Record quarter Q2 FY27 revenue was ₹196.7 cr (+21% YoY) and EBITDA ₹73.2 cr (+32% YoY), both the highest-ever quarterly figures, with EBITDA margin at 37.2%.
  2. Nandesari supplies Management expects commercial supplies from the FDA-approved Nandesari facility to commence in H2 FY27, subject to customer qualification.
  3. AbsorBis AbsorBis growth from new customers and Magnesium Bisglycinate approvals is positioned as a key driver over the next 2–3 years.
  4. Margin pressure PAT margin fell to 26.3% in Q2 FY27 from 28.7% in Q2 FY26, with elevated logistics costs cited.

Original filing on BSE

Sudeep Pharma Limited Q2 FY27 results

As filed: Revenue ₹197 cr (+21% year on year), EBITDA ₹73.2 cr (+31% year on year), PAT ₹51.8 cr (+10% year on year), EBITDA margin 37.2% (+288 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹158 cr, EBITDA ₹54.9 cr, PAT ₹40.6 cr, EBITDA margin 34.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹158 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +48.3% in 30 days (Nifty 500: −1.8%).
  • Q4 FY26: Revenue ₹182 cr, EBITDA ₹62.6 cr, PAT ₹48.5 cr, EBITDA margin 34.3%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹182 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +26.2% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹172 cr, EBITDA ₹60.0 cr, PAT ₹47.7 cr, EBITDA margin 34.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹172 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −8.7% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹163 cr, EBITDA ₹56.0 cr, PAT ₹47.0 cr, EBITDA margin 34.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹163 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −14.7% in 28 days (Nifty 500: −0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Sudeep Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.